Gain Therapeutics (GANX) Enterprise Value (2020 - 2025)
Gain Therapeutics (GANX) has 6 years of Enterprise Value data on record, last reported at -$8.8 million in Q3 2025.
- For Q3 2025, Enterprise Value rose 26.67% year-over-year to -$8.8 million; the TTM value through Sep 2025 reached -$8.8 million, up 26.67%, while the annual FY2024 figure was -$10.4 million, 38.16% up from the prior year.
- Enterprise Value reached -$8.8 million in Q3 2025 per GANX's latest filing, down from -$6.7 million in the prior quarter.
- Across five years, Enterprise Value topped out at -$6.7 million in Q2 2025 and bottomed at -$46.6 million in Q1 2021.
- Average Enterprise Value over 5 years is -$21.5 million, with a median of -$16.9 million recorded in 2024.
- Peak YoY movement for Enterprise Value: tumbled 391.46% in 2021, then surged 60.44% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$36.9 million in 2021, then soared by 45.4% to -$20.1 million in 2022, then grew by 16.6% to -$16.8 million in 2023, then surged by 38.16% to -$10.4 million in 2024, then grew by 15.27% to -$8.8 million in 2025.
- Per Business Quant database, its latest 3 readings for Enterprise Value were -$8.8 million in Q3 2025, -$6.7 million in Q2 2025, and -$9.1 million in Q1 2025.